Search

everythinglearnresearchcommunity

for

Search:↓

The conversation is about the quality of RU58841 powder from Shaanxi Laon Biotech. The user is inquiring if anyone has experience with this product.

Korean scientists developed a red light therapy that reduces a hair loss marker by 92%. Users discussed the benefits and drawbacks of natural sunlight versus red light caps for hair health, with some suggesting supplements for vitamin D.

Shiseido RCH-01 and Replicel's upcoming trial data release. Users discuss expected release timelines and clarify quarter dates.

Concerns about the long-term safety of VDPHL01, an extended-release minoxidil, due to potential risks similar to Cantu syndrome, were raised, highlighting the lack of monitoring for chronic connective tissue changes. The conversation suggests that while the treatment may improve hair growth, it could lead to issues not detected in short-term trials.

The conversation discusses using NAC (N-Acetyl Cysteine) alongside minoxidil and finasteride for hair loss, with some users noting potential hairline improvement and increased energy. The original poster reduced their finasteride dosage due to mental decline and anxiety, and while NAC's effects on hair are anecdotal, it is considered low-risk with other health benefits.

The conversation discusses various theories of hair loss, including DHT sensitivity and genetic factors, with the user willing to use themselves for research due to having a hair loss gene but different hair loss patterns compared to their brothers. Specific treatments were not mentioned in the provided text.

The conversation discusses the application frequency of Koshine 1% for hair loss, with conflicting instructions between Amazon and the main website. The user is unsure whether to apply it once or twice daily.

SCUBE3 is available online but poses risks like tumor promotion and high costs. Users advise against using it due to health concerns and inefficacy as a standalone treatment.

Hair loss discussion includes treatments like hinoki tree oil and procyanidin b2. Experiences and effectiveness of these treatments are shared.

The conversation discusses the differences between KB solution and PG + Ethanol solution for RU58841 in treating hair loss. It compares the effectiveness and properties of these two solutions.

The conversation discusses the removal of Breezula phase II 12-month results by Cassiopea and the search for the original data. Concerns were raised about potential negative long-term effects on hair growth, such as androgen receptor upregulation.

The conversation discusses GT20029, a compound by Kintor Pharma that degrades androgen receptors and is in trials, with potential as a hair loss cure. Another promising treatment mentioned is an antibody that blocks prolactin and has shown positive results in macaques.

The conversation discusses the best carrier for RU58841, comparing Ethanol and PEG400. The user seeks advice on which carrier is more effective.

Scientists found hidden stem cells that might reactivate hair growth. The discussion includes treatments like Minoxidil, finasteride, and RU58841.

Hopeful treatments for hair loss, including Verteporfin, Androgen Receptor Degradation, and SCUBE3. These treatments offer potential solutions to slow or stop the effects of androgens on the scalp.

An 18-year-old experienced severe side effects, including heart palpitations and high blood pressure, after using RU58841 once, leading to a referral to cardiology for suspected left ventricular hypertrophy. The user regrets using RU58841 and seeks advice on recovery, while others suggest preexisting conditions or genetic predispositions may be factors.

The conversation is about the release timeline for clinical trial results and the availability of Breezula, a hair loss treatment. The user is not comfortable buying it as a research drug from China.

The conversation discusses a live stream presentation on Pelage PP405 for hair regrowth, with skepticism about its effectiveness compared to minoxidil. Some users express doubt and suggest sticking to proven treatments like minoxidil, finasteride, and RU58841.

The conversation discusses topical androgen receptor blockers for hair loss, mentioning Clascoterone, Pyrilutamide, GT20029, and RU58841. Ketoconazole's effectiveness and application methods are also debated.

The conversation is about a user preparing to join the ABS-201 clinical trial for hair loss treatment, which involves a prolactin inhibitor. The user plans to update others on their progress if enrolled.

CRISPR treatments for blood disorders have been approved, leading to discussions about its potential for treating hair loss (AGA). A study showed that editing a gene related to DHT sensitivity could lead to hair regrowth, suggesting CRISPR may eventually be used for AGA, but it's expected to be expensive and not soon available.

GT20029 and CosmeRNA are both potential hair loss treatments; GT20029 breaks down the androgen receptor, while CosmeRNA prevents its production. Continuous use is needed, but less frequently than current treatments like Minoxidil and Finasteride.

The conversation discusses the potential of a new hair loss treatment, GT20029, which may prevent hair loss by destroying androgen receptors on the scalp. Users express hope for the treatment's success and speculate on its usage routine, effectiveness, and possible side effects.

Stress can lead to hair loss by affecting hair-follicle stem cells, and this loss is harder to recover from if one has male pattern baldness (MPB). Treatments like finasteride and minoxidil are used to address hair loss, but stress-related hair loss differs from androgenic alopecia.

The conversation discusses the safety and trustworthiness of ordering RU58841 from Lyphar Biotech in China, with a focus on pricing and reliability. The user is seeking advice on whether to proceed with the purchase or consider alternative sources.

The conversation is a satirical expression of frustration over hair loss, mentioning treatments like spironolactone, microneedling, and topical applications, with references to various hair loss products and personalities in the community.

12 companies having drugs or therapies in clinical trials during 2023, with various molecules and phases of trial; the probability that some may fail; and progress being made in the field.

SCUBE3 clinical trials for hair loss treatment to start this year. Treatment may involve regular, painless scalp injections to maintain hair growth.

Adding exosomes to a treatment of dutasteride and minoxidil for hair loss increased hair count by 55% at 6 months and 46% at 1 year compared to the control group. The control group did not receive exosomes or PRP.

Minoxidil can be effectively delivered through nanoemulsions containing eucalyptol or oleic acid, enhancing its diffusivity and targeting hair follicles. This contradicts the advice against mixing minoxidil with oils in topical formulations.